Related Experiment Video
Updated: Mar 14, 2026
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Interferon β associated nephropathy in a Multiple Sclerosis patient: A case and review
Musa Ozturk1, Fulya Basoglu1, Murvet Yilmaz2
1Department of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Tevfik Saglam Cad No:25/2, 34147 Bakirkoy, Istanbul, Turkey.
Background:
Interferon beta (IFN β) subtypes are largely used as immunomodulatory agents in Multiple Sclerosis (MS) treatment. While being generally well tolerated, they can cause various side effects. Adverse effects related to kidney are rarely reported.
Case Report:
We report a 32 years old male patient who developed nephrotic syndrome while receiving IFN β for MS. Biopsy showed focal segmental glomerulosclerosis. He went into remisson after cessation of drug and with the aid of angiotensin II antagonists. Here, we report this case and a review of similar cases reported in literature.
Conclusions:
Although it's a rare adverse effect and tend to show good prognosis physicians should pay careful attention to symptoms and findings of nephropathy during follow ups of patients under treatment with these agents.
Insights
Interferon beta (IFN β) treatment for Multiple Sclerosis (MS) can rarely cause kidney problems like nephrotic syndrome. Prompt recognition and management of these rare adverse effects are crucial for patient recovery.
Area of Science:
- Nephrology
- Immunology
- Neurology
Background:
- Interferon beta (IFN β) is a common immunomodulatory treatment for Multiple Sclerosis (MS).
- While generally safe, IFN β can cause various side effects, with renal adverse events being rare.
- Understanding potential renal complications is vital for long-term MS management.
Observation:
- A 32-year-old male patient developed nephrotic syndrome during IFN β therapy for MS.
- Kidney biopsy revealed focal segmental glomerulosclerosis (FSGS) as the cause of nephrotic syndrome.
- The patient achieved remission after discontinuing IFN β and receiving angiotensin II antagonists.
Findings:
- This case highlights a rare but serious renal adverse effect of IFN β therapy.
- Focal segmental glomerulosclerosis (FSGS) is a potential manifestation of IFN β-induced nephropathy.
- Cessation of the drug and supportive treatment can lead to favorable outcomes.
Implications:
- Physicians must monitor patients on IFN β for early signs of kidney disease.
- Awareness of this rare side effect is important for timely diagnosis and intervention.
- Early detection and management of IFN β-associated nephropathy can improve patient prognosis.
